Author Archives: Pharmaceutical Technology

Roche Takes a Step Forward with Personalized Medicine

By Pharmaceutical Technology | Published: September 14, 2011
Roche took a step forward in personalized medicine with the approval earlier this month of a new drug and related diagnostic to treat certain forms of metastatic melanoma. Roche’s strategy of developing drugs and related diagnostics shows the potential business and therapeutic value of personalized medicines.
Posted in CRO/Sponsor, Trial Design | Tagged , , , , , , , , , , | Leave a comment

Pfizer’s Biosimilar Strategy

By Pharmaceutical Technology | Published: July 11, 2011
Revenue from the sale of biosimilars is expected to grow from $311 million in 2010 to $2–$2.5 billion in 2015, according to IMS Health in their report, The Global Use of Medicines: Outlook Through 2015  released in May 2011,. With all that revenue to be captured, it is no surprise that large pharmaceutical companies are [...]
Posted in CRO/Sponsor | Tagged , , , , | Leave a comment

Failure Rates for Phase II Trials

By Pharmaceutical Technology | Published: May 16, 2011
Success rates have dropped 10% during the period 2008–2009 compared with success rates in 2006–2007. A report published by the Center for Medicines Research (a Thompson Reuters business) published in the April 2011 issue of Nature Reviews Drug Discovery, reported that the success rate from 2008–2009 was 18%, versus 28% in 2006–2007.  Of 108 trials [...]
Posted in Uncategorized | Tagged , , , , , , | 1 Comment

Leaner, Meaner R&D

By Pharmaceutical Technology | Published: April 6, 2011
A sizeable chunk of Big Pharma’s sales will fall off the dreaded patent cliff before the year is out. Patent expirations will allow competitors to market, and patients to buy, generic versions of branded drugs. A renewed focus on discovering and developing new therapies would seem to be the obvious solution for Big Pharma. Yet [...]
Posted in CRO/Sponsor, Sites | 2 Comments

FDA, Pharma, and Alliance Partner to Treat TB

By Pharmaceutical Technology | Published: March 23, 2010
The FDA Commissioner is expected to help launch the Critical Path to TB Drug Regimens (CPTR)—an initiative aimed at accelerating the development and approval of new treatments for tuberculosis (TB). Supporting the initiative are the TB Alliance, the Bill & Melinda Gates Foundation, the Critical Path Institute (C-Path), and 10 pharmaceutical companies: Johnson & Johnson, [...]
Posted in Regulatory, Uncategorized | Tagged , , , , , , , , , , , , | Leave a comment